Moody Aldrich Partners LLC grew its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 47.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 67,880 shares of the company's stock after purchasing an additional 21,983 shares during the quarter. HealthEquity makes up about 1.3% of Moody Aldrich Partners LLC's investment portfolio, making the stock its 22nd biggest position. Moody Aldrich Partners LLC owned 0.08% of HealthEquity worth $5,999,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the business. Transce3nd LLC acquired a new stake in HealthEquity in the 4th quarter valued at $29,000. Versant Capital Management Inc acquired a new stake in shares of HealthEquity in the first quarter valued at about $28,000. Smartleaf Asset Management LLC raised its holdings in shares of HealthEquity by 34.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock valued at $37,000 after buying an additional 98 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its position in HealthEquity by 1,934.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 468 shares of the company's stock worth $45,000 after acquiring an additional 445 shares in the last quarter. Finally, Lindbrook Capital LLC boosted its holdings in HealthEquity by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 750 shares of the company's stock worth $72,000 after acquiring an additional 162 shares during the period. Hedge funds and other institutional investors own 99.55% of the company's stock.
Insider Buying and Selling
In other HealthEquity news, EVP Elimelech Rosner sold 58,000 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.56, for a total transaction of $6,528,480.00. Following the transaction, the executive vice president owned 75,689 shares of the company's stock, valued at approximately $8,519,553.84. This trade represents a 43.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jon Kessler sold 97,767 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $112.05, for a total transaction of $10,954,792.35. Following the transaction, the director directly owned 75,000 shares in the company, valued at approximately $8,403,750. The trade was a 56.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 295,700 shares of company stock valued at $32,968,990 in the last quarter. Company insiders own 1.50% of the company's stock.
HealthEquity Stock Down 1.7%
NASDAQ HQY traded down $1.73 during trading hours on Friday, reaching $99.55. 627,812 shares of the company traded hands, compared to its average volume of 862,960. The company has a 50 day moving average of $99.74 and a two-hundred day moving average of $98.29. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of 0.50. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $116.65. The stock has a market capitalization of $8.61 billion, a PE ratio of 72.66, a PEG ratio of 1.57 and a beta of 0.49.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. The company had revenue of $330.80 million for the quarter, compared to the consensus estimate of $322.25 million. During the same period last year, the firm posted $0.80 EPS. As a group, equities analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current year.
Wall Street Analyst Weigh In
HQY has been the subject of several analyst reports. Royal Bank Of Canada upped their target price on shares of HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a research note on Wednesday, June 4th. Raymond James Financial upgraded shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and decreased their target price for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Deutsche Bank Aktiengesellschaft upped their target price on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, June 5th. Barrington Research upped their target price on shares of HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, June 5th. Finally, KeyCorp decreased their target price on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, HealthEquity currently has a consensus rating of "Buy" and a consensus target price of $118.09.
Get Our Latest Analysis on HealthEquity
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading

Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.